Drug Trial Radar · NCT00343096
Randomized Trial Comparing 3 Routes of Delivering Lorazepam to Children.
Last checked: Nov 19, 2026Latest source record: Jul 10, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
800
Actual
Start
Jun 2006
Primary completion
Mar 2009
Study completion Mar 2009
Sponsor
- Lead sponsor
- Kamuzu University of Health SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 22, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 months, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to address the hypothesis that Lorazepam (an anticonvulsant) is as effective when given via the intranasal or buccal route as the intravenous route in terminating convulsions in children.
Conditions
- Status Epilepticus
- Convulsions
Interventions
LorazepamDrug
All doses 0.1mg/kg once, repeat after 10 minutes x1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Whether cessation of fit was achieved within ten minutes or not.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Queen Elizabeth Central Hospital, Paediatric Dept, Box 360
Blantyre, Malawi
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.